Universidade Estadual Paulista (UNESP), Faculdade de Medicina de Botucatu, Departamento de Cirurgia, Botucatu, SP, Brazil.
Universidade Estadual Paulista (UNESP), Faculdade de Medicina de Botucatu, Unidade de Gastroenterologia Pediátrica, Botucatu, SP, Brazil.
J Pediatr (Rio J). 2019 Jan-Feb;95(1):27-33. doi: 10.1016/j.jped.2017.10.011. Epub 2018 Jan 5.
Evaluate the effect of combinations of green banana biomass and laxatives in children and adolescents with chronic constipation.
This was a randomized study of 80 children and adolescents with functional constipation according to the Rome IV Criteria, who were divided into five groups: (1) green banana biomass alone; (2) green banana biomass plus PEG 3350 with electrolytes; (3) green banana biomass plus sodium picosulfate; (4) PEG 3350 with electrolytes alone; and (5) sodium picosulfate alone. Primary outcome measure was the reduction of the proportion of patients with Bristol Stool Form Scale ratings 1 or 2. Secondary outcome measures were: increase of the proportion of >3 bowel movements/week and reduction of the proportion of fecal incontinence, straining on defecation, painful defecation, blood in stool, abdominal pain, and decreased laxative doses.
On consumption of green banana biomass alone, a statistically significant reduction was observed in the proportion of children with Bristol Stool Form Scale rating 1 or 2, straining on defecation, painful defecation, and abdominal pain. Conversely, no reduction was observed in fecal incontinence episodes/week, blood in stool, and no increase was observed in the proportion of children with >3 bowel movements/week. The percentage of children who required decreased laxative dose was high when green banana biomass was associated with sodium picosulfate (87%), and PEG 3350 with electrolytes (63%). Green banana biomass alone and associated with laxatives was well tolerated, and no adverse effects were reported.
Green banana biomass is advantageous as an adjunct therapy on functional constipation, mainly for reducing doses of laxatives.
评估绿色香蕉生物量与泻药联合应用于儿童和青少年慢性便秘的效果。
这是一项随机研究,纳入了 80 名符合罗马 IV 标准的功能性便秘儿童和青少年,将其分为五组:(1)单独使用绿色香蕉生物量;(2)绿色香蕉生物量联合聚乙二醇 3350 电解质散;(3)绿色香蕉生物量联合匹可硫酸钠;(4)单独使用聚乙二醇 3350 电解质散;(5)单独使用匹可硫酸钠。主要结局指标为布里斯托粪便形状量表评分 1 或 2 的患者比例降低。次要结局指标为:每周排便次数大于 3 次的患者比例增加,粪便失禁、排便费力、排便疼痛、粪便带血、腹痛和减少泻药剂量的患者比例降低。
单独使用绿色香蕉生物量时,布里斯托粪便形状量表评分 1 或 2 的患者比例、排便费力、排便疼痛和腹痛均显著降低。然而,每周粪便失禁发作次数、粪便带血以及每周排便次数大于 3 次的患者比例无明显降低。绿色香蕉生物量联合匹可硫酸钠(87%)和聚乙二醇 3350 电解质散(63%)时,需要减少泻药剂量的患儿比例较高。单独使用绿色香蕉生物量或联合使用泻药均具有良好的耐受性,未报告不良反应。
绿色香蕉生物量作为功能性便秘的辅助治疗方法具有优势,主要可减少泻药的剂量。